Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

s for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios has received Orphan Drug designation from both the FDA and the European Commission for KB001-A for the treatment of CF patients with Pa lung infection. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies. KaloBios plans to begin the phase 2 portion of this study in AML and MDS before the end of 2013.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

    Forward Looking Statements

    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the statements under the heading "Anticipated Upcoming Milestones for 2013-2014"; and statements regarding the company's clinical development of
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... week that the U.S. surgeon general issued a 101-page ... Montana State University published a paper breaking new ground ... cell responds when exposed to ultraviolet (UV) light. ... by the UV rays found in sunlight. This damage ... eye diseases. , "Our paper advances foundational knowledge ...
    (Date:7/31/2014)... Most people are familiar with Hibiscus flowers- they ... where they are commonly planted in the landscape. ... - are endangered species. , Only a relatively ... aware of an equally beautiful and intriguing related ... literally "brother of Hibiscus". , Brother of Hibiscus ...
    (Date:7/31/2014)... , July 31, 2014 ... unique and innovative smart technologies; companies turn towards digital ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ... Inc. (NASDAQ: GOOG ) and Microsoft Corporation ... company focused on the growing m-commerce market, announces a ...
    Breaking Biology News(10 mins):New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3Brother of Hibiscus is found alive and well on Maui 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6
    ... cancer have remained largely unchanged over the past 60 years, ... disease with a very different theory of its origin that ... a billion years ago. In this month,s ... "physics of cancer", Paul Davies, principal investigator at Arizona State ...
    ... In the world, there are a lot of small ... at least convert to something useful, according to University ... dioxide, the greenhouse gas most responsible for far-reaching effects ... that can be transformed into the valuable agricultural fertilizer ...
    ... Ann Liebert, Inc., publishers announces the launch of ... innovative, peer-reviewed journal on this rapidly growing disruptive technology. ... 2013, and quarterly thereafter in 2014. Editor-in-Chief Hod Lipson, ... Lab at the Sibley School of Mechanical and Aerospace ...
    Cached Biology News:Cancer is a result of a default cellular 'safe mode,' physicist proposes 2Diamond catalyst shows promise in breaching age-old barrier 2
    (Date:7/31/2014)... July 31, 2014 According to ... "Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, ... - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - ... 2013 - 2019," the global electrodes market for medical ... and is estimated to reach a market worth USD ...
    (Date:7/31/2014)... Senomyx , Inc. (NASDAQ: ... taste science technologies to discover, develop, and commercialize ... ingredient supply industries, today reported financial results for ... second quarter with $33.6 million in cash and ... past quarter Senomyx achieved another important milestone with ...
    (Date:7/31/2014)... Calif. (PRWEB) July 31, 2014 Held ... diagnosed patients with an overview of the disease and ... of drug side effects, as well as updates on ... grateful to Dr. Sandy Srinivas for organizing this educational ... of kidney cancer. “Sandy and her colleagues have put ...
    (Date:7/31/2014)... Canada (PRWEB) July 31, 2014 ... some of the first transcriptome-wide analyses appearing around ... standard assay for RNA measurement. In the last ... throughput, more specific, work with smaller input amounts, ... tissues (eg, blood samples). On the bioinformatics side, ...
    Breaking Biology Technology:Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2
    ... agents is time-consuming and expensive. Pharmaceutical companies may have ... bind a target molecule before they hit upon a ... Munich led by Professor Dieter Braun, a member of ... a partner in NanoTemper (an LMU spin-off), have now ...
    ... New ... ... 2010 -- Model N , Inc., the leader in Revenue Management solutions, today ... Model N Revenue Management Suite by allowing business users to rapidly develop contract documents ...
    ... ... ... ... ...
    Cached Biology Technology:A hot road to new drugs 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 3Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 4Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 5Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 2Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 3Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 4Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 5Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism 6
    ... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
    ... potential applications for the use of small ... expression via the RNA interference,(RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... enzymatically, and then transfected into the target ...
    ... The HybArray 12™ is an automated hybridization ... The system automates both the hybridization and ... glass slides. A single instrument can process ... in pairs and has multi-protocol software, enabling ...
    ... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
    Biology Products: